|2.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|3.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|5.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
|1.||Kantarjian, Hagop: 114 articles (09/2015 - 01/2002)|
|2.||Marcucci, Guido: 92 articles (11/2015 - 09/2003)|
|3.||Ravandi, Farhad: 88 articles (11/2015 - 02/2004)|
|4.||Cortes, Jorge: 82 articles (09/2015 - 08/2002)|
|5.||Garcia-Manero, Guillermo: 77 articles (12/2015 - 01/2002)|
|6.||Faderl, Stefan: 76 articles (07/2015 - 08/2002)|
|7.||Andreeff, Michael: 71 articles (07/2015 - 01/2002)|
|8.||Appelbaum, Frederick R: 64 articles (08/2015 - 01/2002)|
|9.||Berdel, Wolfgang E: 59 articles (09/2015 - 02/2002)|
|10.||Bloomfield, Clara D: 59 articles (04/2014 - 08/2002)|
|1.||Cytarabine (Cytosar-U)FDA LinkGeneric
11/01/2009 - "The most effective regimen for patients with acute myeloid leukemia (AML) who do not achieve complete remission (CR) after one course of cytarabine and an anthracycline has not been extensively studied. "
01/01/1990 - "In addition, exposure of leukemic myeloblasts to Ara-C and dCyd for 96 h in culture medium lacking PHA-LCM eliminated the secondary plating efficiency (PE2) of leukemic colonies in 11 of 13 samples assayed and reduced values dramatically in the remaining 2. Substantial preservation of CFU-GM formation was also noted when normal bone marrow samples depleted of T cells and marrows obtained from two patients with ANLL in remission were assayed. "
08/01/2000 - "The Eastern Cooperative Oncology Group (ECOG) conducted a prospective phase III study in patients with relapsed/refractory acute myeloid leukemia (AML) to evaluate whether administration of repeated courses of low-dose cytarabine (LDAC) maintenance therapy after induction of complete remission in advanced AML would improve disease-free and overall survival. "
09/01/2014 - "We prospectively evaluated 2 postconsolidation strategies, administered according to the mobilization outcome, in 72 acute myeloid leukemia (AML) fit elderly patients, achieving complete remission after the first high-dose cytarabine-based induction. "
01/01/2013 - "This is an important step to improve the efficacy of cytarabine for the treatment of acute myeloid leukemia. "
|2.||Daunorubicin (Cerubidine)FDA LinkGeneric
05/01/2000 - "De novo ANLL at diagnosis that achieved complete remission (CR) were significantly more sensitive to daunorubicin compared to those who didn't achieve CR (P<0.05). "
02/10/2013 - "Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group."
01/01/2015 - "High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials."
01/01/2013 - "A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor."
10/06/2011 - "A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia."
|3.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
08/01/1982 - "Finally, the present data are extrapolated to the current treatment of human acute myelocytic leukemia in complete remission with high-dose cyclophosphamide in combination with supralethal total-body irradiation."
01/01/1983 - "Efficacy of high-dose cyclophosphamide in combination with total-body irradiation in the treatment of acute myelocytic leukemia: studies in a relevant rat model."
12/15/1984 - "Four patients with acute myeloid leukemia (AML) were treated with high-dose cyclophosphamide and total body irradiation followed by reinfusion of a portion of their own bone marrow collected during remission. "
12/01/1986 - "Seventy-five patients with acute nonlymphoblastic leukemia (ANL) in first remission were treated with cyclophosphamide, 60 mg/kg on each of two consecutive days followed by total body irradiation (TBI) at an exposure rate of 4-6 cGy/min from two opposing 60Co sources. "
08/01/1982 - "Seventeen patients, ages 6--28, with ANLL in first bone marrow remission, received cyclophosphamide and total body irradiation using a radiation scheme of 750 rad (7.5 Gy) total dose, delivered at a dose rate of 26 rad (26 cGy) per minute. "
|4.||Etoposide (VP 16)FDA LinkGeneric
12/01/1992 - "In a randomized trial in previously untreated patients with ANLL, etoposide significantly prolonged remission duration. "
02/01/1997 - "Ten patients received HDAC/VP-16 as post-remission intensification therapy; five patients (four ANLL, one relapsed ALL) remain in second CR at 56, 26, 9, 5 and 2 months. "
02/01/1991 - "Etoposide is active in ANLL and prolongs remission when used as induction therapy."
11/01/1981 - "We conclude that the intensive treatment with VP-16-213 plus 5AZ can effectively induce remission in patients with refractory advanced acute nonlymphocytic leukemia."
07/01/2000 - "[Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia--the JALSG-AML-92 Study. "
|5.||Granulocyte Colony-Stimulating Factor (G-CSF)IBA
01/01/2003 - "Complete remission induced by G-CSF in a patient with acute myeloid leukemia with t(8;21)(q22;q22)."
09/01/1997 - "Complete remission in three patients with acute myeloblastic leukemia by administration of G-CSF without antileukemic agents."
06/01/1995 - "G-CSF combined conditioning regimen seems to be effective for ANLL in complete remission (CR) probably by in vivo purging of residual leukemic cells. "
09/17/2009 - "In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation."
07/01/2008 - "G-CSF-induced remission in two cases of acute myeloid leukemia."
11/01/1996 - "High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia."
07/01/2013 - "The second case, a 60-year-old woman with acute myelogenous leukemia, underwent allogeneic HSCT with the conditioning regimen consisting of ivBu (12.8 mg/kg) and fludarabine (150 mg/kg). "
07/01/2012 - "Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia."
07/01/2010 - "Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients."
01/01/2004 - "Use of fludarabine in the treatment of acute myeloid leukemia."
|7.||Mitoxantrone (Novantrone)FDA LinkGeneric
01/01/1985 - "Of the 25 patients who received mitoxantrone 10 mg/m2 X 5, two of 10 with ANLL in relapse, one of five with ALL in relapse achieved complete remission, and one of seven with blastic phase CML responded. "
06/01/2004 - "Mitoxantrone (MTZ) has been shown to be effective in the treatment of newly diagnosed acute myeloblastic leukemia (AML). "
10/01/1992 - "The study confirms the efficacy of the mitoxantrone-containing combination as a first-line therapy for ANLL."
03/01/1987 - "A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia."
08/01/2013 - "Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia."
06/30/2011 - "IL-2 monotherapy has been evaluated in several randomized clinical trials (RCTs) for remission maintenance in patients with acute myeloid leukemia (AML) in first complete remission (CR1), and none demonstrated a significant benefit of IL-2 monotherapy. "
12/01/1997 - "Several studies have been conducted in Italy to assess the activity of recombinant interleukin-2 (rIL-2) in patients with relapsed-refractory acute myelogenous leukemia (AML) and in AML patients in second complete remission (CR) who are not eligible for standard therapy. "
10/01/2002 - "We have treated 20 patients, affected by acute myelogenous leukemia in advanced phase of the disease, with intravenous high-dose recombinant interleukin-2 (IL2) as induction treatment, achieving a complete remission (CR) in 11/20 of patients (55%). "
04/01/1999 - "The authors investigated whether IL-2 may improve the duration of complete remission (CR) and survival in acute myelogenous leukemia (AML) patients in first CR. "
04/01/1999 - "A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission."
|9.||Busulfan (Busulfex)FDA Link
03/01/2013 - "A wide range of busulfan exposures were targeted for children with the same disease (eg, 39 target busulfan exposures for the 264 children diagnosed with acute myeloid leukemia). "
02/01/2005 - "Between March 1993 and June 2002, we treated 33 relapsed acute myelogenous leukemia (AML) patients with busulfan-based preparative regimens and selective TCD. "
09/01/2000 - "Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia."
01/01/1994 - "Moreover, patients with acute myelogenous leukemia or those transplanted after busulfan or total-body irradiation conditioning regimens had a slower engraftment (p < 0.08). "
12/01/1961 - "The role of Myleran in acute myelocytic leukemia."
|10.||gemtuzumab (gemtuzumab ozogamicin)FDA Link
07/01/2010 - "Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin."
06/01/2007 - "Complete remission induced by gemtuzumab ozogamicin in a Jehovah's Witness patient with acute myelogenous leukemia."
05/01/2004 - "High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients."
07/01/2012 - "Resistance to gemtuzumab ozogamicin (GO) hampers the effective treatment of refractory acute myeloid leukemia (AML). "
04/01/2009 - "Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia."
|1.||Drug Therapy (Chemotherapy)
05/01/1992 - "Most results obtained by different study and analytic designs favor that matched allogeneic BMT is superior to chemotherapy in young adults with ANLL in first remission. "
09/10/2013 - "Despite reaching remission with traditional chemotherapy, most adult patients with acute myeloid leukemia (AML) will relapse and die of their disease. "
07/01/2011 - "The most effective regimen for acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after two different courses of front-line chemotherapy has not been established. "
08/01/2010 - "Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction chemotherapy. "
10/01/2007 - "Most adult patients with acute myeloid leukemia (AML) who reach a complete remission (CR) after induction chemotherapy will relapse if they do not receive further therapy. "
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
03/01/1992 - "In the attempt to evaluate the role of Autologous and Allogeneic Bone Marrow Transplantation, we have retrospectively analyzed 159 patients with Acute Myeloid Leukemia in first complete remission treated in our Unit, most of whom were referred from other Institutions. "
02/01/1992 - "New approaches are needed to increase the cure rate substantially, and autologous bone marrow transplantation appears to be the most promising treatment modality in acute myeloid leukemia. "
01/01/1992 - "Is allogeneic bone marrow transplantation the best treatment for young adult patients with acute myeloid leukemia in first complete remission. "
05/01/2004 - "On the basis of observations from dog models and human studies, we hypothesized that a low-dose (550 cGy), single-exposure total body irradiation (TBI)-based regimen would result in improved survival when given to adult patients with acute myelogenous leukemia (AML) who were undergoing unrelated donor bone marrow transplantation in complete remission (CR). "
07/01/1993 - "This study compares outcomes of autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in untreated first relapse (REL1) or in second complete remission (REM2). "
08/20/2009 - "In acute myelocytic leukemia (AML), for patients who receive transplants during first complete remission (CR1), no prospective randomized study has compared relapse incidence (RI) to cell source. "
05/01/2015 - "This retrospective study considered the outcomes of 181 patients with acute myeloid leukemia (AML) transplanted in second complete remission (CR2) between January 2005 and April 2012 and who received either a myeloablative autologous stem cell transplant (Auto-SCT; n = 82; median age: 48 years; median follow-up: 45 months) or an umbilical cord blood (UCB) allogeneic SCT (n = 99, median age: 46 years; median follow-up: 36 months; conditioning regimens: myeloablative n = 21, reduced n = 78; single unit n = 37, double units n = 62). "
01/15/2015 - "Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (EPI) into favorable, intermediate, and poor-risk groups based on duration of first CR, cytogenetics, age, and transplant history. "
02/01/2014 - "We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported to the Center for International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor from 2000 to 2010. "
04/01/2010 - "Acute myeloid leukemia: when to transplant in first complete remission."
|4.||Transplantation (Transplant Recipients)
02/01/2013 - "Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research."
11/01/1990 - "A randomized trial of 12.0 Gy versus 15.75 Gy of total body irradiation (TBI) was performed in patients with acute myeloid leukemia undergoing allogeneic marrow transplantation while in first complete remission. "
06/01/2014 - "We studied patients with acute myeloid leukemia (AML) over age 50 and in first complete remission (CR1) after adult unrelated donor (URD) (n = 441, 8/8 HLA matched; n = 94, 7/8 HLA matched) or umbilical cord blood (UCB; n = 205) transplantations. "
11/01/2013 - "For acute myeloid leukemia, only disease status (beyond first complete remission) remained a significant adverse risk factor for LFS 2 or more years after transplantation. "
09/01/2012 - "We used the European Group for Blood and Marrow Transplantation (EBMT) ALWP data to compare the outcome of mobilized peripheral blood stem cells (PBSC) (n = 1430) vs. bone marrow (BM) (n = 107) for acute myelogenous leukemia (AML) patients with complete remission that underwent RIC-alloSCT from compatible sibling donors. "
|5.||Stem Cell Transplantation
08/01/2006 - "Most studies showing that autologous stem cell transplantation (ASCT) is feasible in older patients with acute myeloid leukemia (AML) referred to highly selected patients considered as eligible after complete remission (CR) achievement and bone marrow or peripheral blood stem cell (PBSC) collection. "
10/01/2014 - "Stem cell transplantation is still the most effective treatment for pediatric acute myeloid leukemia (AML). "
04/01/2008 - "Our period analysis reveals major improvement on the population level in long-term prognosis of younger patients with acute myeloblastic leukemia, most likely explained by multiple incremental improvements in care including better and more specific diagnosis, improvements in and extension of the use of stem cell transplantation and high dose therapy, and improved supportive care."
06/10/2009 - "Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials."
03/01/2007 - "Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study."